NURIX THERAPEUTICS INC
NASDAQ: NRIX (Nurix Therapeutics, Inc.)
Kemas kini terakhir: 3 jam lalu23.97
0.06 (0.25%)
| Penutupan Terdahulu | 23.91 |
| Buka | 24.00 |
| Jumlah Dagangan | 1,268,246 |
| Purata Dagangan (3B) | 1,990,541 |
| Modal Pasaran | 2,478,637,312 |
| Harga / Jualan (P/S) | 31.08 |
| Harga / Buku (P/B) | 5.14 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Jul 2026 |
| Margin Operasi (TTM) | -340.67% |
| EPS Cair (TTM) | -2.60 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 11.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.54% |
| Nisbah Semasa (MRQ) | 6.26 |
| Aliran Tunai Operasi (OCF TTM) | -191.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -106.56 M |
| Pulangan Atas Aset (ROA TTM) | -31.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -64.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Nurix Therapeutics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -1.63 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.41% |
| % Dimiliki oleh Institusi | 111.85% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| General Atlantic, L.P. | 31 Mar 2026 | 4,101,865 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HANSEN GWENN | - | 22.46 | -5,394 | -121,149 |
| RING CHRISTINE | - | 22.46 | -28,935 | -649,880 |
| Jumlah Keseluruhan Kuantiti Bersih | -34,329 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -771,029 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 22.46 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| RING CHRISTINE | Pegawai | 25 Jun 2026 | Jual automatik (-) | 28,935 | 22.46 | 649,880 |
| RING CHRISTINE | Pegawai | 25 Jun 2026 | Pelaksanaan pilihan | 28,935 | - | - |
| HANSEN GWENN | Pegawai | 25 Jun 2026 | Jual automatik (-) | 5,394 | 22.46 | 121,149 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |